← back to search

Wei Deng

Guangzhou University of Chinese Medicine · CN
Area of research
Surgery · Pulmonary and Respiratory Medicine
Research interest
Research interests include Esophageal Cancer Research and Treatment, Lung Cancer Diagnosis and Treatment, Endometrial and Cervical Cancer Treatments, and Cancer Immunotherapy and Biomarkers.
h-index
29
citations
2,437
works
151
NIH funding
primary concept
email

Recent publications

Sanhuang Fukang oil alleviates X-ray-induced skin injury by reducing inflammation and apoptosis: an in vivo study
Frontiers in Pharmacology 2026cited by 0position: middledoi
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial
Nature Communications 2025cited by 15position: middledoi
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
Gynecologic Oncology 2025cited by 9position: middledoi
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
Journal of Clinical Oncology 2025cited by 5position: middledoi
Correlation between stress hyperglycemia ratio and risk of acute respiratory distress syndrome in patients with sepsis: a MIMIC-IV cohort study
Scientific Reports 2025cited by 2position: middledoi
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical carcinoma following radical hysterectomy and lymphadenectomy: Results of NRG oncology/GOG-263
Gynecologic Oncology 2025cited by 1position: middledoi
Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial
Radiotherapy and Oncology 2025cited by 1position: middledoi
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279
Journal of Clinical Oncology 2024cited by 16position: middledoi
AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway
Molecular Carcinogenesis 2024cited by 15position: middledoi
Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma
BMC Cancer 2024cited by 7position: middledoi
Effectiveness of S-1–Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma
JAMA Network Open 2023cited by 27position: middledoi
GOG 3026 A phase II trial of letrozole + ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube or peritoneum: A GOG foundation study (001)
Gynecologic Oncology 2023cited by 22position: middledoi
The critical role of pancreatic stone protein/regenerating protein in sepsis-related multiorgan failure
Frontiers in Medicine 2023cited by 10position: middledoi
Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience
Frontiers in Oncology 2022cited by 36position: middledoi
Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
Journal of Hepatocellular Carcinoma 2022cited by 31position: middledoi
Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis
Therapeutic Advances in Medical Oncology 2022cited by 5position: middledoi
Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey
Acta Oncologica 2021cited by 30position: middledoi
Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China
Radiation Oncology 2021cited by 11position: middledoi
[Preliminary report on partial pressure changes of oxygen and carbon dioxide in umbilical artery and vein before and after the first breath in Chinese neonates I-The group difference of partial pressure of oxygen and carbon dioxide between umbilical artery and vein in newborns].
PubMed 2021cited by 2position: middledoi
[The effectiveness of different respiration models to the amplitude of waveform information in arterial blood gas].
PubMed 2021cited by 1position: middledoi
[Preliminary report on partial pressure changes of oxygen and carbon dioxide in umbilical artery and vein before and after the first breath in Chinese neonates II-The personalized analysis of partial pressure of oxygen and carbon dioxide difference between umbilical artery and vein at same time in same newborn].
PubMed 2021cited by 0position: middledoi
[The experimental evidence of waveform information in arterial blood gas by beat-by-beat sampling method in human body-the differences of waveform information between arterial and venous blood samples].
PubMed 2021cited by 0position: middledoi
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)
Gynecologic Oncology 2020cited by 153position: middledoi
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Clinical Cancer Research 2020cited by 57position: middledoi
Technical Note: Integrating an open source Monte Carlo code “MCsquare” for clinical use in intensity‐modulated proton therapy
Medical Physics 2020cited by 51position: firstdoi
NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer
Radiotherapy and Oncology 2019cited by 48position: middledoi
Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Gynecologic Oncology 2019cited by 32position: middledoi
Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
Gynecologic Oncology 2018cited by 16position: middledoi
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
Journal of Clinical Oncology 2017cited by 361position: middledoi
A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis
Oncotarget 2017cited by 13position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Heather A. Lankes · NRG Oncology4 papers (2019–2025)Yin-Jun Li · Hebei Medical University4 papers (2021–2021)Zheng Ci · Hebei Medical University4 papers (2021–2021)Jin Xie · Hubei University of Medicine4 papers (2022–2024)Ming-Xin Ma · Hebei Medical University4 papers (2021–2021)Renfeng Shan · Nanchang University4 papers (2022–2024)Jyoti Mayadev · La Jolla Alcohol Research4 papers (2024–2025)Yu-Xin Zou · Army Medical University4 papers (2021–2021)Robert S. Mannel · NRG Oncology4 papers (2020–2025)Zhigao Hu · Fudan University4 papers (2022–2024)Wan-Gang Ge · Hebei Medical University4 papers (2021–2021)Jiabao Zhu · Huazhong University of Science and Technology4 papers (2021–2021)Xing‐Guo Sun · Dalian Medical University4 papers (2021–2021)Yan Cui · Ericsson (Sweden)4 papers (2021–2021)Yan Huang · Wuhan University4 papers (2021–2021)Charles A. Leath · St. Vincent's Birmingham4 papers (2024–2025)Guoqing Zhu · Nanchang University4 papers (2022–2024)Xiaoyue Tan · Nankai University4 papers (2021–2021)Laihui Luo · Nanchang University4 papers (2022–2024)David S. Miller · Gynecologic Oncology Group3 papers (2019–2024)